30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Sanofi Mitigates Viscosupplement Sales Losses in 2Q19 -



Sanofi continues to correct course on its orthobiologics business, with a -5.4% revenue decline in 2Q19 after sustaining an almost -20% decline in 2018.


Quarterly Highlights

  • Continued struggles in the U.S. were offset somewhat by high-single-digit growth in ex-U.S. markets.
  • Sanofi seems to have stabilized its orthobiologics business after a span of four consecutive quarters with at least a -20% sales decline between 4Q17 and 3Q18. The average quarterly decline since then is -3.7%.


Performance by Segment

Synvisc and Synvisc-One sales on an as-reported basis are as follows ($MM).

  2Q19 2Q18 % Chg % Chg
Orthobiologics $97.7 $103.4 -$5.6 -5.4%
  1H19 1H18 % Chg % Chg
Orthobiologics $174.1 $179.8 -$5.6 -3.1%



Sales by Geographic Region

Synvisc and Synvisc-One sales by geographic region are as follows ($MM).

  2Q19 2Q18 % Chg % Chg
US $66.3 $74.2 -$7.9 -10.6%
Ex-US $31.5 $29.2 $2.2 7.7%
   Europe $9.0 $7.9 $1.1 14.3%
   Emerging Markets $18.0 $18.0 $0.0 0.0%
   Rest of World $4.5 $3.4 $1.1 33.3%
Total $97.7 $103.4 -$5.6 -5.4%


Sources: Sanofi

Mike Evers is ORTHOWORLD’s Market Analyst. He can be reached by email.

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.